BioNTech Faces Two-Pronged ASCO Test as Investors Seek Validation for Cancer Pipeline Beyond COVID

The weekend will determine whether BioNTech’s oncology bet gains traction or stalls. As the American Society of Clinical Oncology (ASCO) annual meeting kicked off in Chicago on Friday, the Mainz-based biotech is preparing to unveil two critical sets of clinical data that could reshape market confidence in its post-COVID identity.

Shares gained 2.68% to close at €82.35 on Friday, lifting the weekly gain to 3.58%. The stock now sits above its 50-day moving average of €81.06 but remains well below the 200-day line at €86.18, with a neutral relative strength index of 53.4. The modest advance suggests investors are holding positions through the weekend rather than making aggressive bets.

Two Pipeline Candidates in the Spotlight

The most immediate catalyst arrives Saturday morning with a presentation on Gotistobart, BioNTech’s CTLA-4-targeting antibody developed in partnership with OncoC4. The data, delivered in an oral session on gynecologic cancers, focuses on overall survival in heavily pretreated patients with platinum-resistant ovarian cancer who received Gotistobart in combination with Merck’s Keytruda (pembrolizumab). The antibody is designed to selectively deplete regulatory T cells in the tumor microenvironment — a mechanism that BioNTech views as a linchpin for future combination strategies across multiple platforms.

But Gotistobart is not the only readout commanding attention. The company’s leading bispecific antibody, Pumitamig, generated encouraging interim data from the dose-optimization portion of the Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer. The results cover both squamous and non-squamous histologies across all PD-L1 expression levels, targeting a large and intensely competitive market. BioNTech is already running a pivotal Phase 3 study where Pumitamig plus chemotherapy goes head-to-head against Merck’s entrenched standard-of-care Keytruda.

Should investors sell immediately? Or is it worth buying BioNTech?

Together, the two drug candidates illustrate the breadth — and the pressure — of BioNTech’s oncology pivot. The company expects to have 15 active Phase 3 studies by year-end and plans seven late-stage oncology data packages this year, including a US filing for Trastuzumab Pamirtecan.

Financial Realities Behind the Science

The urgency to demonstrate clinical progress is underpinned by shrinking COVID-19 vaccine revenue. First-quarter sales fell to $138.0 million, while the net loss widened to $622.3 million. Research and development spending reached $651.6 million, a level that underscores the high cost of maintaining a broad pipeline.

Full-year revenue guidance remains at $2.3–2.6 billion, but BioNTech is simultaneously tightening its belt. The restructuring announced earlier this year — affecting roughly 1,860 positions through production exits in Idar-Oberstein, Marburg, Singapore and some CureVac sites — is expected to generate annual savings of about $584.9 million by 2029. On the capital allocation side, a $19.6 billion cash pile provides ample runway, and a planned share buyback of up to $1 billion over 12 months signals management’s view that the stock is undervalued.

Analysts broadly agree with that assessment, though the range of views is wide. The average price target among 17 analysts stands at $125.45, well above the recent US-traded level. Canaccord Genuity trimmed its target from $171 to $158 but remains positive, while Leerink is more cautious at $94.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The Weekend Verdict

For BioNTech, the ASCO data represent more than a scientific milestone — they are a test of whether the pipeline can generate registration-quality evidence that justifies the valuation discount. The stock’s €82.35 close on Friday offers a temporary floor. How that level holds when trading resumes on Monday will depend entirely on whether the survival signals from Gotistobart and the activity data from Pumitamig convince investors that the oncology strategy is on track.

The EU approval update for the COVID vaccine in toddlers, announced on the same day, barely registered. All eyes in Chicago are on the cancer data — and the clock is ticking toward the next chapter.

Ad

BioNTech Stock: New Analysis - 30 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69449786 |